FDAmanufacturing / CMC77% confidence
CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative
Source: FDA
Why This Matters
Why this matters: provides agency context on manufacturing / CMC that may shape timing or evidence expectations for Dr. Reddy's; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Chemotherapy
- Sub-indication
- General
Related signal: FDA Grants AP Status for Dr. Reddy's Capecitabine ANDA204345